BMPR2 Dosage Gates BMP9/10 Signaling Output in Pulmonary Artery Endothelium
Cells · 2026
DOI: 10.3390/cells15060492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Kit-Yee Chu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Michigan State University, 603 Wilson Road, East Lansing, MI 48824, USA. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein Receptors, Type II, Pulmonary Artery, Signal Transduction, Growth Differentiation Factor 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is characterized by dysfunction and remodeling of the pulmonary artery endothelium and smooth muscle. In heritable PAH, heterozygous loss-of-function mutations in the type II Bone Morphogenetic Protein (BMP) receptor gene (BMPR2) are the most common genetic cause. However, the mechanisms by which reduced BMPR2 levels alter endothelial signaling to drive PAH pathogenesis remain incompletely understood. To determine how BMPR2 levels govern signaling output and endothelial functional responses, we modulated BMPR2 expression in human pulmonary artery endothelial cells (PAECs) and assessed ligand-dependent SMAD1/5/8 signaling, proliferation, and caspase-3/7 activity. We found that BMP9 and BMP10 robustly activated SMAD1/5/8 signaling and promoted proliferation in PAECs, whereas the other ligands in this panel did not elicit a comparable signaling or proliferative response under these assay conditions. A moderate (~50%) reduction in BMPR2 protein levels (an in vitro approximation of haploinsufficiency) attenuated BMP9/10-induced SMAD1/5/8 activation, abolished proliferative responses, and was associated with a modest increase in caspase-3/7 activity, consistent with caspase pathway activation and early stress/injury signaling. Under BMPR2-limiting conditions, BMP9/10 responses became sensitive to Activin type II receptor blockade by bimagrumab, consistent with a context-dependent contribution of Activin type II receptors. Conversely, BMPR2 overexpression enhanced BMP9/10-dependent SMAD signaling and proliferation. Together, these findings support a receptor–dosage model where physiological BMPR2 expression is required to sustain homeostatic BMP9/10 signaling in pulmonary artery endothelium. This framework provides a basis for interpreting context-dependent pathway effects in PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Michigan State University, 603 Wilson Road, East Lansing, MI 48824, USA.
- Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Boston, MA 02129, USA.
ORCID-Profile: Kit-Yee Chu
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Chu, K. Y., Thamilselvan, V., Crawford, A. N., Yu, P. B., & Martinez-Hackert, E. (2026). BMPR2 Dosage Gates BMP9/10 Signaling Output in Pulmonary Artery Endothelium. Cells. https://doi.org/10.3390/cells15060492
Vancouver
Chu KY, Thamilselvan V, Crawford AN, Yu PB, Martinez-Hackert E. BMPR2 Dosage Gates BMP9/10 Signaling Output in Pulmonary Artery Endothelium. Cells. 2026. doi:10.3390/cells15060492
BibTeX
@article{Chu2026,
author = {Chu, Kit-Yee and Thamilselvan, Vijayalakshmi and Crawford, Amberly N and Yu, Paul B and Martinez-Hackert, Erik},
title = {BMPR2 Dosage Gates BMP9/10 Signaling Output in Pulmonary Artery Endothelium},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15060492}
}
EUVIMED